» Articles » PMID: 30104569

A Multi-state Model of Chemoresistance to Characterize Phenotypic Dynamics in Breast Cancer

Overview
Journal Sci Rep
Specialty Science
Date 2018 Aug 15
PMID 30104569
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The development of resistance to chemotherapy is a major cause of treatment failure in breast cancer. While mathematical models describing the dynamics of resistant cancer cell subpopulations have been proposed, experimental validation has been difficult due to the complex nature of resistance that limits the ability of a single phenotypic marker to sufficiently identify the drug resistant subpopulations. We address this problem with a coupled experimental/modeling approach to reveal the composition of drug resistant subpopulations changing in time following drug exposure. We calibrate time-resolved drug sensitivity assays to three mathematical models to interrogate the models' ability to capture drug response dynamics. The Akaike information criterion was employed to evaluate the three models, and it identified a multi-state model incorporating the role of population heterogeneity and cellular plasticity as the optimal model. To validate the model's ability to identify subpopulation composition, we mixed different proportions of wild-type MCF-7 and MCF-7/ADR resistant cells and evaluated the corresponding model output. Our blinded two-state model was able to estimate the proportions of cell types with an R-squared value of 0.857. To the best of our knowledge, this is the first work to combine experimental time-resolved drug sensitivity data with a mathematical model of resistance development.

Citing Articles

Computational identification of surface markers for isolating distinct subpopulations from heterogeneous cancer cell populations.

Gardner A, Jost T, Morgan D, Brock A NPJ Syst Biol Appl. 2024; 10(1):120.

PMID: 39420005 PMC: 11487074. DOI: 10.1038/s41540-024-00441-6.


Computational identification of surface markers for isolating distinct subpopulations from heterogeneous cancer cell populations.

Gardner A, Jost T, Brock A bioRxiv. 2024; .

PMID: 38854060 PMC: 11160629. DOI: 10.1101/2024.05.28.596337.


Development of adaptive anoikis resistance promotes metastasis that can be overcome by CDK8/19 Mediator kinase inhibition.

Monavarian M, Page E, Rajkarnikar R, Kumari A, Macias L, Massicano F bioRxiv. 2023; .

PMID: 38106208 PMC: 10723298. DOI: 10.1101/2023.12.04.569970.


Cell Population Growth Kinetics in the Presence of Stochastic Heterogeneity of Cell Phenotype.

Wang Y, Zhou J, Pedrini E, Rubin I, Khalil M, Taramelli R ArXiv. 2023; .

PMID: 37904742 PMC: 10614996.


Cytotoxic and chemomodulatory effects of Phyllanthus niruri in MCF-7 and MCF-7 breast cancer cells.

Abdel-Sattar O, Allam R, Al-Abd A, Avula B, Katragunta K, Khan I Sci Rep. 2023; 13(1):2683.

PMID: 36792619 PMC: 9932073. DOI: 10.1038/s41598-023-29566-0.


References
1.
Harris L, Frick P, Garbett S, Hardeman K, Paudel B, Lopez C . An unbiased metric of antiproliferative drug effect in vitro. Nat Methods. 2016; 13(6):497-500. PMC: 4887341. DOI: 10.1038/nmeth.3852. View

2.
Hardeman K, Peng C, Paudel B, Meyer C, Luong T, Tyson D . Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition. Sci Rep. 2017; 7:42604. PMC: 5311997. DOI: 10.1038/srep42604. View

3.
Panetta J . A mathematical model of breast and ovarian cancer treated with paclitaxel. Math Biosci. 1997; 146(2):89-113. DOI: 10.1016/s0025-5564(97)00077-1. View

4.
Mumenthaler S, DAntonio G, Preziosi L, Macklin P . The Need for Integrative Computational Oncology: An Illustrated Example through MMP-Mediated Tissue Degradation. Front Oncol. 2013; 3:194. PMC: 3724164. DOI: 10.3389/fonc.2013.00194. View

5.
Montagna E, Cancello G, Dellapasqua S, Munzone E, Colleoni M . Metronomic therapy and breast cancer: a systematic review. Cancer Treat Rev. 2014; 40(8):942-50. DOI: 10.1016/j.ctrv.2014.06.002. View